drugset
drugset / Trial / NCT00889421

Apremilast in the Treatment of Uveitis

NCT00889421 ↗

Phase 1/2 Terminated 3 enrolled Oregon Health and Science University Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Timeline

Start
2009-11
Primary completion
2011-06
Completion
2011-06

Outcome

Outcome not reported

Stopped (Enrollment): “Investigator discretion due to lack of efficacy in three subjects enrolled”

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg Oral

Indications

uveitis